Phase 2 AURA-IPF Study
A Phase 2 Study Evaluating the Safety and Efficacy of AP02 (inhaled nintedanib) in Participants with Idiopathic Pulmonary Fibrosis (IPF)
visit study #NCT07194382 clinical trials.GOV >
Phase 1a Study
A Phase 1 Study of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow® Nebulizer System in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis or Progressive Fibrosing Interstitial Lung Disease
Phase 1b Study
A Phase 1 Study of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow® Nebulizer System to Evaluate the Safety, Tolerability, and Pharmacokinetics of AP02 in Healthy Volunteers